Aspirin for MI primary prevention
Executive Summary
Use of aspirin for primary prevention of myocardial infarction will be considered by FDA's Cardiovascular & Renal Drugs Advisory Committee in consultation with Nonprescription Drugs Advisory Committee on Dec. 8. Bayer asked FDA in a Feb. 11 citizen petition to allow the indication based on a meta-analysis of five studies showing a 32% reduction in MI in patients who had not previously had a cardiovascular event. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8:30 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...